Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease

Blood Cells, Molecules, and Diseases

Volumn 68, Issue , 2018, Pages 203-208

  Biegstraaten, M ^a   Cox, T M ^b   Belmatoug, N ^c   Berger, M G ^d   Collin Histed, T ^e   Vom Dahl, S ^f   Di Rocco, M ^g   Fraga, C ^h   Giona, F ⁱ   Giraldo, P ^j   Hasanhodzic, M ^k   Hughes, D A ^l   Iversen, P O ^m   Kiewiet, A I ^a   Lukina, E ⁿ   Machaczka, M ^o   Marinakis, T ^p   Mengel, E ^q   Pastores, G M ^r   Plockinger U ^s   Rosenbaum, H ^t   Serratrice, C ^u   Symeonidis, A ^v   Szer, J ^w   Timmerman, J ^x   Tylki Szymanska A ^y   Weisz Hubshman, M ^z   Zafeiriou, D I ^aa   Zimran, A ^ab   Hollak, C E M ^a   more..

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c Centre de recherche sur l'habitat ENSA Paris Val de Seine   (France)

^d UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^e European Gaucher Alliance   (United Kingdom)

^f UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^g G GASLINI INSTITUTE   (Italy)

^h HDES Hospital   (Portugal)

ⁱ SAPIENZA UNIVERSITY OF ROME   (Italy)

^j CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^k UNIVERSITY CLINICAL CENTER TUZLA   (Bosnia and Herzegovina)

^l UNIVERSITY COLLEGE LONDON   (United Kingdom)

^m UNIVERSITY OF OSLO   (Norway)

ⁿ NATIONAL RESEARCH CENTER FOR HEMATOLOGY   (Russian Federation)

^o KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^p G GENNIMATAS GENERAL HOSPITAL   (Greece)

^q UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^r MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^s CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^t The Center for Consultant Medicine   (Israel)

^u GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^v UNIVERSITY OF PATRAS   (Greece)

^w ROYAL MELBOURNE HOSPITAL   (Australia)

^x Dutch Patient Organization for Children and Adults with Metabolic Disorders   (Netherlands)

^y CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^z TEL AVIV UNIVERSITY   (Israel)

^aa ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^ab SHAARE ZEDEK MEDICAL CENTER   (Israel)

more..

Author keywords

Delphi study; Gaucher disease; Management goals; PROMs; Therapy

Indexed keywords

VITAMIN D;

ABDOMINAL DISEASE; ARTICLE; BONE DISEASE; CHOLECYSTITIS; CHOLELITHIASIS; CLINICAL FEATURE; CONSENSUS DEVELOPMENT; DELPHI STUDY; DISEASE SEVERITY; EARLY DIAGNOSIS; EUROPE; FATIGUE; GAUCHER DISEASE TYPE 1; HEMATOLOGIC DISEASE; HUMAN; IRON DEFICIENCY ANEMIA; MONOCLONAL IMMUNOGLOBULINEMIA; PATIENT MONITORING; PRIORITY JOURNAL; QUALITY OF LIFE; SOCIAL PARTICIPATION; VITAMIN BLOOD LEVEL; COMPLICATION; CONSENSUS; DISEASE MANAGEMENT; GAUCHER DISEASE; PSYCHOLOGY;

CONSENSUS; DISEASE MANAGEMENT; EUROPE; GAUCHER DISEASE; HUMANS; QUALITY OF LIFE;

EID: 85006057007     PISSN: 10799796     EISSN: 10960961     Source Type: Journal    
DOI: 10.1016/j.bcmd.2016.10.008     Document Type: Article

References (30)

1. Meikle, P.J., et al. Prevalence of lysosomal storage disorders. JAMA 281:3 (1999), 249–254.
2. Grabowski, G.A., Kolodny, E., Weinreb, N.J., Scriver, C.R., Beaudet, A.L., Valle, D., et al. (eds.) Gaucher disease: phenotypic and genetic variation, 2006 (2006]; Available from: http://genetics.accessmedicine.com/mmbid/public/co_contents/toc_part16.html).
3. Barton, N.W., et al. Replacement therapy for inherited enzyme deficiency — macrophage-targeted glucocerebrosidase for Gaucher's disease. N. Engl. J. Med. 324:21 (1991), 1464–1470.
4. Grabowski, G.A., Leslie, N., Wenstrup, R., Enzyme therapy for Gaucher disease: the first 5 years. Blood Rev. 12:2 (1998), 115–133.
5. Zimran, A., et al. Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience. Blood 115:23 (2010), 4651–4656.
6. Zimran, A., et al. Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood 118:22 (2011), 5767–5773.
7. Weinreb, N.J., et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher registry. Am. J. Med. 113:2 (2002), 112–119.
8. Cox, T.M., et al. The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. J. Inherit. Metab. Dis. 26:6 (2003), 513–526.
9. Hollak, C.E., et al. Miglustat (Zavesca) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme. Pharmacoepidemiol. Drug Saf. 18:9 (2009), 770–777.
10. Cox, T.M., et al. Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial. Lancet 385:9985 (2015), 2355–2362.
11. Pastores, G.M., et al. Therapeutic goals in the treatment of Gaucher disease. Semin. Hematol. 41 (2004), 4–14.
12. Deegan, P.B., et al. Osseous manifestations of adult Gaucher disease in the era of enzyme replacement therapy. Medicine (Baltimore) 90:1 (2011), 52–60.
13. Arends, M., et al. Malignancies and monoclonal gammopathy in Gaucher disease; a systematic review of the literature. Br. J. Haematol. 161:6 (2013), 832–842.
14. Mistry, P.K., et al. Pulmonary hypertension in type 1 Gaucher's disease: genetic and epigenetic determinants of phenotype and response to therapy. Mol. Genet. Metab. 77:1–2 (2002), 91–98.
15. Bembi, B., et al. Gaucher's disease with Parkinson's disease: clinical and pathological aspects. Neurology 61:1 (2003), 99–101.
16. Langeveld, M., et al. Type I Gaucher disease, a glycosphingolipid storage disorder, is associated with insulin resistance. J. Clin. Endocrinol. Metab. 93:3 (2008), 845–851.
17. van Dussen, L., et al. Modelling Gaucher disease progression: long-term enzyme replacement therapy reduces the incidence of splenectomy and bone complications. Orphanet J. Rare Dis., 9, 2014, 112.
18. Pavlova, E.V., et al. Inhibition of UDP-glucosylceramide synthase in mice prevents Gaucher disease-associated B-cell malignancy. J. Pathol. 235:1 (2015), 113–124.
19. Weldring, T., Smith, S.M., Patient-reported outcomes (PROs) and patient-reported outcome measures (PROMs). Health Serv. Insights 6 (2013), 61–68.
20. Hsu, C.C., Sandford, B.A., The Delphi technique: making sense of consensus. Pract. Assess. Res. Eval., 12(10), 2007.
21. Glassel, A., et al. Content validity of the Extended ICF Core Set for stroke: an international Delphi survey of physical therapists. Phys. Ther. 91:8 (2011), 1211–1222.
22. Smid, B.E., et al. Uncertain diagnosis of Fabry disease: consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance. Int. J. Cardiol. 177:2 (2014), 400–408.
23. Zimran, A., et al. Prediction of severity of Gaucher's disease by identification of mutations at DNA level. Lancet 2:8659 (1989), 349–352.
24. Di Rocco, M., et al. A new severity score index for phenotypic classification and evaluation of responses to treatment in type I Gaucher disease. Haematologica 93:8 (2008), 1211–1218.
25. Weinreb, N.J., et al. Evaluation of disease burden and response to treatment in adults with type 1 Gaucher disease using a validated disease severity scoring system (DS3). Orphanet J. Rare Dis., 10, 2015, 64.
26. Hollak, C.E., et al. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J. Clin. Invest. 93:3 (1994), 1288–1292.
27. Boot, R.G., et al. Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Blood 103:1 (2004), 33–39.
28. Stein, P., et al. Hyperferritinemia and iron overload in type 1 Gaucher disease. Am. J. Hematol. 85:7 (2010), 472–476.
29. Symeonidis, A., et al. Achievement of the goals of therapy for patients with Gaucher disease on enzyme replacement therapy is higher among earlier-treated patients and is not influenced by disease severity at presentation. Haematologica, 92(Suppl. 1), 2007, 277.
30. Hollak, C.E., Weinreb, N.J., The attenuated/late onset lysosomal storage disorders: therapeutic goals and indications for enzyme replacement treatment in Gaucher and Fabry disease. Best Pract. Res. Clin. Endocrinol. Metab. 29:2 (2015), 205–218.